Immunoglobulin (Human)
Privigen
- Dosage form
- Tablet
- Available strengths
- 10% (100 mg/mL); available in 2.5 g, 5 g, 10 g, 20 g, and 40 g vials
- Drug class
- Immune globulin (polyvalent human IgG) - passive immunizing and replacement therapy agent
- Common brand
- Privigen
Clinical overview. Immunoglobulin (Privigen) is a 10% intravenous immune globulin prepared from pooled human plasma, used to treat primary and secondary immune deficiencies, immune thrombocytopenic purpura, and chronic inflammatory demyelinating polyneuropathy. It carries a boxed warning for kidney failure and blood clot risk, so it is given as a slow, monitored infusion with attention to hydration and infusion rate.
Indication
Common therapeutic uses
- Immunoglobulin (Privigen) is used to treat primary and secondary immune deficiencies, including common variable immunodeficiency, X-linked and congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiency.
- Immunoglobulin is used in patients over age 15 with immune thrombocytopenic purpura (ITP) to rapidly raise platelet counts and prevent bleeding.
- Immunoglobulin is used as an immune-modulating treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder.
Pregnancy
Risk assessment and monitoring considerations
- The safety of immunoglobulin in human pregnancy has not been established in controlled clinical trials.
- Immunoglobulin is known to cross the placenta, with transfer increasing in the third trimester.
- Immunoglobulin should be used in pregnancy only when the expected benefits outweigh the potential risks.
Breastfeeding
Infant exposure considerations
- Immunoglobulins pass into breast milk and may help protect a nursing infant against certain infections through the gut lining.
- Immunoglobulin should be used while breastfeeding only when the expected benefits outweigh the potential risks.
Geriatrics
Dosing and tolerability considerations
- Patients over 65 years of age are at higher risk of kidney problems with immunoglobulin therapy and should be infused at the slowest practical rate.
- Clinical studies did not include enough patients aged 65 and older to determine whether they respond differently than younger adults.
Pediatrics
Use in children and adolescents
- Immunoglobulin (Privigen) is authorized for children aged 3 to 16 years with primary immune deficiency, with no meaningful differences in safety or effectiveness compared with adults.
- Safety and effectiveness have not been established in children under 3 years of age, in children under 15 with ITP, or in children under 18 with CIDP.
- Dosing in children is based on body weight, the same as in adults, and adjusted to the clinical response.
Dosage & Administration
Practical dosing and administration
- For primary and secondary immune deficiency, the usual dose is 200 to 800 mg per kilogram of body weight, given every 3 to 4 weeks and adjusted to maintain an adequate antibody trough level.
- For immune thrombocytopenic purpura, the usual regimen is given over 2 consecutive days.
- For chronic inflammatory demyelinating polyneuropathy, a higher loading regimen is given over several days, followed by lower maintenance doses roughly every 3 weeks.
- The infusion is started at a slow rate and gradually increased as tolerated, particularly in patients receiving immunoglobulin for the first time, switching products, or after a long gap since the last dose.
- Patients at risk of kidney problems or blood clots should receive the lowest effective dose at the slowest practical infusion rate.
- Patients should be well hydrated before the infusion begins.
- A missed dose should be given as soon as possible to maintain an adequate antibody level.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Excessive doses of immunoglobulin can lead to fluid overload and increased blood thickness (hyperviscosity), particularly in elderly patients or those with existing heart or kidney problems.
- There is no specific antidote; management of overdose is supportive and directed at the resulting fluid or viscosity problems.
Common side effects
Frequently reported tolerability concerns
- Headache is common, especially with infusion.
- Chills may occur.
- Fatigue may occur.
- Nausea or vomiting may occur.
- Fever may occur.
- Back pain or general body pain may occur.
- Dizziness may occur.
- Cough or stomach discomfort may occur.
- Diarrhea may occur.
- Joint pain and low blood pressure may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Kidney problems, including acute kidney failure, have occurred with immunoglobulin products, particularly in patients with existing kidney disease, diabetes, older age, or dehydration.
- Blood clots, including heart attack, stroke, pulmonary embolism, and deep vein thrombosis, have occurred, even in patients without known risk factors.
- Serious allergic reactions, including anaphylactic shock, can occur, even in patients who tolerated immunoglobulin before.
- A sudden drop in blood pressure with an anaphylactoid-type reaction can occur, rarely.
- Aseptic meningitis, with severe headache, neck stiffness, fever, and sensitivity to light, can develop within hours to two days of an infusion and usually resolves after the drug is stopped.
- Blood cell destruction (hemolytic anemia), sometimes requiring a blood transfusion, has occurred, more often with high doses or in patients with non-O blood types.
- Transfusion-related acute lung injury (TRALI), a serious lung reaction causing breathing difficulty, can occur within hours of an infusion.
- Severe skin reactions, including Stevens-Johnson syndrome and bullous dermatitis, have been reported.
- Because immunoglobulin is made from pooled human plasma, there is a theoretical risk of transmitting infectious agents, including viruses, despite donor screening and viral inactivation steps during manufacturing.
- Seek urgent medical attention for chest pain, sudden weakness on one side of the body, severe shortness of breath, leg swelling or pain, a severe headache with neck stiffness, or signs of a serious allergic reaction.
Use with caution
Situations requiring closer assessment
- Use with caution in patients with pre-existing kidney impairment, diabetes, sepsis, or dehydration, using the lowest effective dose and slowest infusion rate.
- Use with caution in patients with risk factors for blood clots, such as older age, prior blood clots, immobility, estrogen use, or an indwelling central venous catheter.
- Use with caution in patients at risk of increased blood thickness (hyperviscosity), such as those with abnormal blood proteins or very high triglycerides.
- Use with caution in patients receiving immunoglobulin for the first time, switching between products, or after a long gap since the last infusion, as reactions are more likely; monitor closely during and after the infusion.
- Use with caution in patients with a rare condition called hyperprolinemia, because Privigen contains the stabilizer L-proline.
- Use with caution in patients with IgA deficiency, given the risk of hypersensitivity reactions to trace IgA in the product.
- Use caution when driving or operating machinery if you experience dizziness, fatigue, or other adverse reactions until they resolve.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with selective IgA deficiency who have known antibodies against IgA.
- Contraindicated in patients who have had an anaphylactic or severe systemic reaction to human immunoglobulin in the past.
Drug interactions
Clinically relevant combinations
- Immunoglobulin can temporarily reduce the effectiveness of live attenuated vaccines, such as measles, mumps, rubella, and varicella, for at least 6 weeks and up to 3 months, and up to a year for measles vaccine.
- Vaccination with a live attenuated vaccine should generally be delayed for about 3 months after immunoglobulin, and the immunizing physician should be told about recent immunoglobulin treatment.
- Interactions with food have not been established.
- Interactions with herbal products have not been established.
- Immunoglobulin can cause a temporary rise in passively transferred antibodies that may interfere with certain blood tests, including some antibody-based blood typing tests.
Food interactions
Meal-related administration
- Immunoglobulin is given only as an intravenous infusion, so food and meal timing do not affect its use.
Time of administration
Practical scheduling
- Immunoglobulin infusions are scheduled and supervised by a healthcare professional at a clinic or infusion centre, so timing is not related to meals.
Storage
Product handling
- Store immunoglobulin (Privigen) either in the refrigerator or at room temperature, between 2°C and 25°C, until the expiry date printed on the vial and carton.
- Do not freeze immunoglobulin.
- Keep the vial in its original carton to protect it from light.
- Discard any partially used vial after 24 hours, as the solution contains no preservative.
Patient take-away
Key counselling points for a quick closing summary
- Immunoglobulin infusions are given in a clinical setting under monitoring, since side effects most often occur during or shortly after the infusion.
- Make sure you are well hydrated before your infusion appointment.
- Tell your healthcare provider about any headache, fever, neck stiffness, chest pain, leg swelling, or breathing difficulty that develops during or after treatment.
- Let your immunization provider know you have recently received immunoglobulin, since it can reduce the effectiveness of certain live vaccines for several months.
- Report any history of blood clots, kidney disease, or migraine-type headaches to your healthcare provider before starting treatment.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.